E hui pū ʻo Innovent me NeoCura ma Kina e loiloi i ka palekana, pharmacokinetics, pharmacodynamics a me ka pono mua o ka hui pū ʻana me ka sintilimab mai Innovent a me NEO_PLIN2101 mai NeoCura i nā maʻi maʻi maʻi, e holomua i ka hoʻomohala ʻana i ka hoʻomohala ʻana o ka immunotherapy hui no nā maʻi maʻi paʻa he nui a hoʻomākaukau e waiho. ka Investigational New Drug (IND) noi i ka National Medical Products Administration (NMPA) i ka wā e hiki mai ana.
Ua ʻōlelo ʻo Dr. Liu Yongjun, Pelekikena o Innovent: “Pīhoihoi mākou i ka paipu R&D ʻokoʻa a NeoCura a me ka hui noiʻi honua, a hauʻoli mākou i ke komo ʻana i kēia hui hoʻolālā e ʻimi i ka waiwai o ka sintilimab i hui pū ʻia me nā lāʻau neoantigen no nā maʻi maʻi paʻa. . Loaʻa iā Innovent kahi pipeline ikaika me nā mana ikaika i ka immunology a me ka biology cancer. I kēia manawa, loaʻa iā mākou nā lāʻau lapaʻau hou ʻelima i ʻae ʻia a hoʻokuʻu ʻia ma Kina a loaʻa iā mākou ma mua o 10 mau lāʻau lapaʻau hou e hoʻokuʻu ʻia i nā makahiki 2-3 e hiki mai ana. Ua hōʻiliʻili kā mākou kahua paʻa piha i ka R&D ikaika, ka hoʻomohala lapaʻau a me ka hiki ke kūʻai aku a kūpono no nā hoa ma ka home a ma waho. Manaʻo mākou e ʻimi hou i nā manawa hou i ka hoʻonui ʻana i nā hōʻailona a me ka hoʻonui ʻana i ka pono therapeutic o sintilimab i hui pū ʻia me nā lāʻau lapaʻau. Ke kakali nei mākou i ka laulima ākea a hohonu ma waena o nā ʻaoʻao ʻelua i ka wā e hiki mai ana. “
Ua ʻōlelo ʻo Dr. Wang Yi, ka mea nāna i hoʻokumu iā NeoCura: "I kēia manawa, ʻo nā lāʻau lapaʻau neoantigen kahi ala lapaʻau e kū nei i ka honua holoʻokoʻa. Ke nānā nei ʻo NeoCura i ka R&D o nā maʻi neoantigen tumor mai kona hoʻokumu ʻia ʻana, me ka manaʻo e lanakila i nā pilikia o ka immunotherapy i loaʻa i ka mālama ʻana i nā maʻi maʻi paʻa ma o ka hoʻohana ʻana i nā ʻenehana hou. ʻO ka hui pū ʻana me Innovent e pāʻani i kahi hana synergistic o nā maʻi neoantigen pilikino a me nā lāʻau antibody monoclonal a e ʻimi pū i ka hopena o ka lāʻau lapaʻau o ka hui pū ʻana i ka mālama ʻana i nā maʻi maʻi paʻa, i manaʻo ʻia e hoʻomaikaʻi i ka helu pane o ka maʻi immunotherapy a lawe mai i nā manawa hou. no ka hoʻohui pū ʻana i ka maʻi maʻi."
He aha e lawe ʻia mai kēia ʻatikala:
- E hui pū ʻo Innovent me NeoCura ma Kina e loiloi i ka palekana, pharmacokinetics, pharmacodynamics a me ka pono mua o ka hui pū ʻana me ka sintilimab mai Innovent a me NEO_PLIN2101 mai NeoCura i nā maʻi maʻi maʻi, e holomua i ka hoʻomohala ʻana i ka hoʻomohala ʻana o ka immunotherapy hui no nā maʻi maʻi paʻa he nui a hoʻomākaukau e waiho. ka Investigational New Drug (IND) noi i ka National Medical Products Administration (NMPA) i ka wā e hiki mai ana.
- ʻO ka hui pū ʻana me Innovent e pāʻani i kahi hana synergistic o nā maʻi neoantigen pilikino a me nā lāʻau antibody monoclonal a e ʻimi pū i ka hopena o ka lāʻau lapaʻau o ka hui pū ʻana i ka mālama ʻana i nā maʻi maʻi paʻa, i manaʻo ʻia e hoʻomaikaʻi i ka helu pane o ka maʻi immunotherapy a lawe mai i nā manawa hou. no ka hoʻohui ʻana i ka maʻi kanesa.
- Ke nānā nei ʻo NeoCura i ka R&D o nā maʻi neoantigen tumor mai kona hoʻokumu ʻana, me ka manaʻo e lanakila i nā pilikia o ka immunotherapy i kēia manawa i ka mālama ʻana i nā maʻi koko paʻa ma o ka hoʻohana ʻana i nā ʻenehana hou.
